|
|
Article: Data Show Sepracor's Lunesta(R) Improved Insomnia in Patients with Co-Existing Generalized Anxiety Disorder.
- Article from:
- Business Wire
- Article date:
- December 5, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Results Presented at American College of Neuropsychopharmacology Annual Meeting
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announces the presentation of results from a Phase IV, 595-patient, double-blind, placebo-controlled, ten-week study evaluating the efficacy and safety of LUNESTA([R]) brand eszopiclone in patients with insomnia and co-existing Generalized Anxiety Disorder (GAD). The results will be presented today at the annual meeting of the American College of Neuropsychopharmacology in Hollywood, Fla.
In this study, patients who met DSM-IV([R]1) criteria for both insomnia and GAD were randomized to receive nightly LEXAPRO([R])brand ...